Genocea Biosciences
100 Acorn Park Drive
Cambridge
Massachusetts
02140
United States
Tel: 617-876-8191
Fax: 617-876-8192
Website: http://www.genocea.com/
Email: website.inquiry@genocea.com
About Genocea Biosciences
Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases.Genocea’s pipeline includes programs addressing genital herpes, pneumococcus, chlamydia, malaria and cancer immunotherapy. We currently have two products in Phase 2 clinical development:
• GEN-003, an immunotherapy to treat patients with genital herpes. We reported positive top-line data from an ongoing Phase 2b dose optimization trial from the immediate post dosing 28-day observation period in May 2015. We identified an improved dose of 60µg per protein/75µg of adjuvant, which demonstrated a highly statistically significant reduction (p>0.0001) from baseline in the viral shedding rate (55%) and genital lesion rate (60%). Data from the six-month and 12-month observation periods in this trial is expected in the fourth quarter of 2015 and the first quarter of 2016, respectively.
Data from the prior Phase 1/2a trial was the first time a therapeutic vaccine candidate has demonstrated significant reductions in the rates of viral shedding and genital lesions in genital herpes patients.
• GEN-004, a universal vaccine which is in Phase 2 development to prevent infections caused by all serotypes of pneumococcus. We have completed enrollment in a Phase 2 human challenge clinical trial and expect to report top-line data in the fourth quarter of 2015.
In a prior Phase 1 study, GEN-004 met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces.
193 articles about Genocea Biosciences
-
Genocea Biosciences Unveils Protective Therapeutic Vaccine for Herpes Simplex Virus Type 2 (HSV-2)
8/6/2012
-
Genocea Biosciences Announces New Research Identifying Potential Vaccine Candidates for Chlamydia
6/7/2012
-
Genocea Biosciences Highlights Key Progress in the Development of its First Vaccine Candidate, Targeting HSV-2
5/4/2012
-
Genocea Biosciences Release: Novel T Cell Antigen Discovery Platform Providing New Momentum on Malaria Vaccine
4/11/2012
-
Genocea Biosciences to Present at the 8th International Symposium on Pneumococci and Pneumococcal Diseases
3/12/2012
-
Genocea Biosciences to Present at Biotech Showcase(TM) 2012
1/3/2012
-
Genocea Biosciences to Present at Biotechnology Industry Organization (BIO) Investor Forum
10/25/2011
-
Isconova and Genocea Biosciences Expand Collaboration
8/22/2011
-
Genocea Biosciences Hires Ravi Venkataramani, Ph.D. as Vice President, Business Development
6/20/2011
-
Genocea Biosciences to Present at the 2011 Biotechnology Industry Organization (BIO) International Convention
5/25/2011
-
Genocea Biosciences to Present at the World Vaccine Congress
3/24/2011
-
Genocea Biosciences to Present at the World Vaccine Congress
3/23/2011
-
Genocea Biosciences to Present at the 5th Biennial Meeting of the Chlamydia Basic Research Society
3/17/2011
-
Genocea Biosciences to Present at the 5th Biennial Meeting of the Chlamydia Basic Research Society
3/17/2011
-
Genocea Biosciences and Children's Hospital Boston Release: New Pneumococcal Vaccine Approach Successful in Early Tests
2/16/2011
-
Genocea Biosciences Names New CEO
2/1/2011
-
Genocea Biosciences Lands Massive $35M Series B Round
1/3/2011
-
Genocea Biosciences Hires Chip Clark as Chief Business Officer
8/12/2010
-
Genocea Biosciences Enters Into Cooperative Research and Development Agreement with U.S. Military to Develop Malaria Vaccine
4/15/2010
-
Genocea Biosciences Signs Exclusive License Agreement with Children's Hospital Boston for Novel Streptococcus Pneumoniae Antigens
3/18/2010